NEW YORK–(BUSINESS WIRE)–Ophthotech today announced that it will report its second quarter 2017 financial and operating results on Wednesday, July 26, 2017.
Author Archive for Business Wire
MedOp Health Confirms Claims on Label
by Business Wire • • 0 Comments
OLDSMAR, Fla.–(BUSINESS WIRE)–MedOp Health announces that it has proven that the new MaxiVision® Meso Plus Formula DOES CONTAIN ALL THE LEVEL OF CAROTENOIDS CLAIMED ON THE LABEL.
Second Sight to Discuss Second Quarter 2017 Financial Results on August 1, 2017 Conference Call
by Business Wire • • 0 Comments
SYLMAR, Calif.–(BUSINESS WIRE)–Second Sight Medical Products, Inc. (NASDAQ:EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to provide some useful vision to blind patients, will release its second quar…
Kala Pharmaceuticals Announces Pricing of Initial Public Offering
by Business Wire • • 0 Comments
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals announced that it has priced its initial public offering.
Visioneering Technologies, Inc. Announces Jim Raulino, OD As Executive Territory Manager, Reno/Sacramento
by Business Wire • • 0 Comments
ATLANTA–(BUSINESS WIRE)–Jim Raulino, OD has joined Visioneering Technologies, Inc., as the company’s Executive Territory Manager for Sacramento and Reno.
Aerie Pharmaceuticals Reports Positive Roclatan™ (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Phase 3 12-month Topline Safety Results
by Business Wire • • 0 Comments
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported the successful 12-month safety results of the Company’s “Mercury 1” Phase 3 registration trial for its fixed-dose combination product candidate, Roclatan™. Mercury 1 is a 12-month safety and efficacy tria
Global Retinal Drugs Market to Grow at a CAGR of 11.6% by 2021 – Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis & Regeneron – Research and Markets
by Business Wire • • 0 Comments
DUBLIN–(BUSINESS WIRE)–The “Global Retinal Drugs Market 2017-2021″ report has been added to Research and Markets’ offering. The global retinal drugs market to grow at a CAGR of 11.66% during the period 2017-2021. The report, Global Retinal Drugs Mark…
Glaukos Corporation to Release Second Quarter 2017 Financial Results after Market Close on August 2
by Business Wire • • 0 Comments
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release second quarter 2017 financial results after the market close on Wednesday, August 2, 2017. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on Aug
Data From BioTime’s Phase I/IIa OpRegen® Trial to be Presented at the 2017 American Academy of Ophthalmology (AAO) Annual Meeting
by Business Wire • • 0 Comments
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that an abstract related to the Company’s retinal tissue implant has been accepted for a paper presentation at the American Academy of Ophthalmology (AAO) annual meeting being held in New Orleans, Louisiana, November 11-14. The abstract accepted for paper presentation is titled, “Phase 1 and 2a Study of
LSGPA Invests an Additional $500,000 in MacuLogix, Inc.
by Business Wire • • 0 Comments
HARRISBURG, Pa.–(BUSINESS WIRE)–#AMD–The Life Sciences Greenhouse of Central Pennsylvania (LSGPA) announced today an additional investment of $500,000 in MacuLogix, Inc. The investment was part of a syndicate with other, unnamed investors and brings LSGPA’s total investment in the Middletown-based firm to over $2 million. MacuLogix is the developer of the AdaptDx, an automated dark adaptometer that enables eye care professionals to diagnose, monitor and treat age-related macular degeneration (AMD)
Global Cosmetic Contact Lenses Market 2017-2021 – Key vendors are The Cooper Companies, Johnson & Johnson, Novartis & Valeant – Research and Markets
by Business Wire • • 0 Comments
DUBLIN–(BUSINESS WIRE)–The “Global Cosmetic Contact Lenses Market 2017-2021″ report has been added to Research and Markets’ offering. The analysts forecast the global cosmetic contact lens market to grow at a CAGR of 4.96% during the period 2017-2021…
Visioneering Technologies, Inc. Appoints Gary Sacks as Executive Territory Manager For New York/Western Massachusetts
by Business Wire • • 0 Comments
ATLANTA–(BUSINESS WIRE)–Gary Sacks has joined Visioneering Technologies, Inc., as Executive Territory Manager, New York/Western Massachusetts
Castle Biosciences’ Uveal Melanoma Test Receives Positive Medicare Local Coverage Determination and Commercial Insurance Positive Coverage Policies
by Business Wire • • 0 Comments
FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced three important milestones in improving access to DecisionDx®-UM, the standard of care prognostic tool for patients with uveal melanoma (UM), an aggressive form of eye cancer. Palmetto GBA, the administrator of the MolDX® program that assesses molecular diagnostic technologies on behalf of the Centers for Medicare and Medicaid Services (CMS),
BioTime to Host Key Opinion Leader Event on the Topic of Dry AMD in New York City
by Business Wire • • 0 Comments
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced today that it will host a Key Opinion Leader event on the topic …
Global Tipiracil / Trifluridine Sales, Price Analysis, & Sales Forecasts 2016-2021 – Research and Markets
by Business Wire • • 0 Comments
DUBLIN–(BUSINESS WIRE)–The “Tipiracil / Trifluridine Sales, Price Analysis, & Sales Forecast – 2017″ report has been added to Research and Markets’ offering. Find out the sales of Tipiracil / Trifluridine worldwide and by countries in North America, Europe, Japan, BRIC, and Australia. Discover the growth trends of Tipiracil / Trifluridine by countries, and also find out sales forecast until 2021. The research also provides Tipiracil / Trifluridine unit price by countries. The sales and pr
RightEye Clinical Case Study Highlights Risk of Long-Term Binocular Vision Issues Following Concussions
by Business Wire • • 0 Comments
WASHINGTON–(BUSINESS WIRE)–#Parkinsons–RightEye announces publication of new clinical case study showing long-term effects of concussions and head trauma on vision issues.
Nightstar Appoints David Lubner to its Board of Directors
by Business Wire • • 0 Comments
BOSTON & LONDON–(BUSINESS WIRE)–Nightstar Appoints David Lubner to its Board of Directors
Top 3 Emerging Trends Impacting the Global Intraocular Lens Market From 2017-2021: Technavio
by Business Wire • • 0 Comments
LONDON–(BUSINESS WIRE)–#MedicalDevices–Technavio’s report on the global intraocular lens market provides an analysis of the most important trends expected to impact the market outlook.
Visioneering Technologies, Inc. Appoints Michelle Kirst as Territory Manager for New Jersey
by Business Wire • • 0 Comments
ATLANTA–(BUSINESS WIRE)–Visioneering Technologies, Inc., welcomes Michelle Kirst as Territory Manager for New Jersey.
Beaver-Visitec International Acquires Vitreq
by Business Wire • • 0 Comments
WALTHAM, Mass.–(BUSINESS WIRE)–Beaver-Visitec International (BVI), a leading global developer, manufacturer, and marketer of specialized surgical devices for the ophthalmic marketplace, announced today it has acquired Vitreq, a next-generation ophthalmic technology company. Additional terms of the transaction were not disclosed. “At Vitreq, it’s our mission to develop reliable, safe, and sophisticated tools that provide surgeons with the support and innovation necessary to perform at the high